PT-141 (bremelanotide) nasal spray showed efficacy for erectile dysfunction in clinical trials, working through brain melanocortin receptors rather than peripheral blood flow — advancing toward potential approval.
Key findingPT-141 intranasal demonstrated ED treatment efficacy in clinical trials through central melanocortin receptor activation, with development progressing
What the researchers found
PT-141 intranasal demonstrated ED treatment efficacy in clinical trials through central melanocortin receptor activation, with development progressing toward potential approval as a first-in-class brain-acting sexual dysfunction therapy.
Why it matters
Advances understanding of pt-141, sexual-health, clinical-trials, receptor-signaling with translational implications.
How the study worked
review study examining pt-141 and sexual-health.
What this study cannot tell us
Study-specific limitations apply; see abstract for details.
How to read the evidence
moderate evidence from review study design.
When this study was published
Published in 2004.
The bigger picture
Contributes to the growing body of peptide research with implications for clinical development and therapeutic applications.
Questions still open
- Further research needed to confirm and extend these findings.
- Clinical translation and safety need evaluation.
- Optimal dosing and delivery require characterization.
Common questions
What was the main focus of this study?
What was discovered?
Read the original research
PT-141 Palatin.
Current opinion in investigational drugs (London, England : 2000), 5(4), 456-62
Citation
Hedlund, Petter. (2004). PT-141 Palatin.. Current opinion in investigational drugs (London, England : 2000), 5(4), 456-62.